164 related articles for article (PubMed ID: 1810195)
1. Penetration of cefotaxime and desacetylcefotaxime into brain abscesses in humans.
Sjölin J; Eriksson N; Arneborn P; Cars O
Antimicrob Agents Chemother; 1991 Dec; 35(12):2606-10. PubMed ID: 1810195
[TBL] [Abstract][Full Text] [Related]
2. Treatment of brain abscess with cefotaxime and metronidazole: prospective study on 15 consecutive patients.
Sjölin J; Lilja A; Eriksson N; Arneborn P; Cars O
Clin Infect Dis; 1993 Nov; 17(5):857-63. PubMed ID: 8286626
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with Streptococcus milleri brain abscesses.
Kowlessar PI; O'Connell NH; Mitchell RD; Elliott S; Elliott TS
J Infect; 2006 Jun; 52(6):443-50. PubMed ID: 16239034
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic modelling of cefotaxime and desacetylcefotaxime--a population study in 25 elderly patients.
Urien S; Laurent N; Barre J; Druguet M; Bouvier D'yvoire M; Maire P
Eur J Clin Pharmacol; 2004 Mar; 60(1):11-6. PubMed ID: 14767629
[TBL] [Abstract][Full Text] [Related]
5. Antibacterial activity of desacetylcefotaxime alone and in combination with cefotaxime.
Neu HC
Rev Infect Dis; 1982; 4 Suppl():S374-8. PubMed ID: 6294786
[TBL] [Abstract][Full Text] [Related]
6. Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review.
Jones RN
Diagn Microbiol Infect Dis; 1995; 22(1-2):19-33. PubMed ID: 7587039
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, and cefotaxime-desacetylcefotaxime in the presence of human serum.
Jones RN; Barry AL
Antimicrob Agents Chemother; 1987 May; 31(5):818-20. PubMed ID: 3606081
[TBL] [Abstract][Full Text] [Related]
8. Prevention of intracranial problems in ear and sinus surgery: a possible role for cefotaxime.
Weiner GM; Williams B
J Laryngol Otol; 1993 Nov; 107(11):1005-7. PubMed ID: 7904618
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of cefotaxime in combination with metronidazole for empirical treatment of brain abscess in clinical practice: a retrospective study of 66 consecutive cases.
Jansson AK; Enblad P; Sjölin J
Eur J Clin Microbiol Infect Dis; 2004 Jan; 23(1):7-14. PubMed ID: 14669073
[TBL] [Abstract][Full Text] [Related]
10. Cefotaxime in brain abscesses.
Martin Luengo F; Poza M; Pérez-Espejo MA; Gómez J
Infection; 1986; 14(2):89-90. PubMed ID: 3710598
[No Abstract] [Full Text] [Related]
11. The synergistic effect of cefotaxime and desacetylcefotaxime against clinical isolates of anaerobic bacteria.
Devlin HR; Boskovski L
Drugs; 1988; 35 Suppl 2():45-50. PubMed ID: 3396488
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of desacetylcefotaxime and the interaction with its parent compound, cefotaxime.
Oizumi K; Hayashi I; Aonuma S; Konno K
Drugs; 1988; 35 Suppl 2():57-61. PubMed ID: 3135170
[TBL] [Abstract][Full Text] [Related]
13. Brain abscess due to Capnocytophaga species, Actinomyces species, and Streptococcus intermedius in a patient with cyanotic congenital heart disease.
Engelhardt K; Kampfl A; Spiegel M; Pfausler B; Hausdorfer H; Schmutzhard E
Eur J Clin Microbiol Infect Dis; 2002 Mar; 21(3):236-7. PubMed ID: 11957031
[No Abstract] [Full Text] [Related]
14. Cefotaxime and desacetylcefotaxime: an example of advantageous antimicrobial metabolism.
Chin NX; Neu HC
Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):21S-31S. PubMed ID: 6086215
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy.
Jones RN; Barry AL; Thornsberry C
Rev Infect Dis; 1982; 4 Suppl():S366-73. PubMed ID: 6294785
[TBL] [Abstract][Full Text] [Related]
16. Microbiology of cerebral abscess at the neurosurgical unit of the National Hospital of Sri Lanka.
Seneviratne Rde S; Navasivayam P; Perera S; Wickremasinghe RS
Ceylon Med J; 2003 Mar; 48(1):14-6. PubMed ID: 12795014
[TBL] [Abstract][Full Text] [Related]
17. Disposition of cefotaxime and its metabolite, desacetylcefotaxime, in rat: application of a pharmacokinetic-protein binding model.
Hakim L; Bourne DW; Triggs EJ
Xenobiotica; 1989 Jul; 19(7):743-54. PubMed ID: 2773510
[TBL] [Abstract][Full Text] [Related]
18. Pilot Study of the Pharmacokinetics of Cefotaxime in Critically Ill Patients with Acute Kidney Injury Treated with Continuous Renal Replacement Therapy.
Koedijk JB; Valk-Swinkels CG; Rijpstra TA; Touw DJ; Mulder PG; van der Voort PH; van 't Veer NE; van der Meer NJ
Antimicrob Agents Chemother; 2016 Jun; 60(6):3587-90. PubMed ID: 27021325
[TBL] [Abstract][Full Text] [Related]
19. Investigation of human bile and serum levels by high pressure liquid chromatography after administration of latamoxef or cefotaxime.
Krausse R; Ullmann U; Brandstetter G; Kratochvil P
Arzneimittelforschung; 1984; 34(12):1787-91. PubMed ID: 6099130
[TBL] [Abstract][Full Text] [Related]
20. Optimal dosing of cefotaxime and desacetylcefotaxime for critically ill paediatric patients. Can we use microsampling?
Guerra Valero YC; Dorofaeff T; Coulthard MG; Sparkes L; Lipman J; Wallis SC; Roberts JA; Parker SL
J Antimicrob Chemother; 2022 Jul; 77(8):2227-2237. PubMed ID: 35678266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
